AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27257981 — intervention group
Group type: COMPARATOR
Intervention: Three consecutive intraarticular injections of 2.5 ml standard linear sodium hyaluronate (Adant) with one week intervals
Number of subjects: 40
Study 24366001 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine and dexmedetomidine (Group LD)
Number of subjects: 48
Study 24366001 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (Group L)
Number of subjects: 48
Study 23469594 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingchang Huashi Recipe (QHR)
Number of subjects: 60
Study 23469594 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine Enteric-coated Tablet (MECT)
Number of subjects: 60
Study 20536953 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 0
Study 20536953 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 0
Study 18034666 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily on the second day, followed by 50 mg diclofenac 1 h after the last dose of voriconazole
Number of subjects: 10
Study 18034666 — intervention group
Group type: COMPARATOR
Intervention: Control phase with a single 50-mg oral dose of diclofenac
Number of subjects: 10
Study 16128370 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 111
Study 16128370 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 111
Study 12375317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 40
Study 10550087 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexSure test
Number of subjects: 394
Study 10550087 — intervention group
Group type: COMPARATOR
Intervention: Enzyme linked immunosorbent assay (ELISA; HM‐CAP)
Number of subjects: 394
Study 10550087 — intervention group
Group type: COMPARATOR
Intervention: H pylori test and refer group
Number of subjects: 394
Study 10550087 — intervention group
Group type: COMPARATOR
Intervention: Direct endoscopy referral group
Number of subjects: 394
Study 7607138 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 ppb nitrous acid
Number of subjects: 11
Study 7607138 — intervention group
Group type: COMPARATOR
Intervention: Filtered room air (control)
Number of subjects: 11
Study 1980733 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Magnesium sulfate (MgS04)
Number of subjects: 13
Study 1980733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MgS04 and salbutamol
Number of subjects: 13
Study 1980733 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol alone
Number of subjects: 13
Study 359108 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (mean dose 2.0 mg)
Number of subjects: 50
Study 359108 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulphate (10 mg)
Number of subjects: 50
Study 359108 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (average 4.6 mg per patient)
Number of subjects: 50
Study 359108 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulphate (average 22.8 mg per patient)
Number of subjects: 50
Study 31852492 — intervention group
Group type: COMPARATOR
Intervention: Mailed notification (usual care)
Number of subjects: 2000
Study 31852492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed notification plus written educational materials (enhanced)
Number of subjects: 2000
Study 31852492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed notification, written educational materials, plus verbal explanation by a promotora (interpersonal)
Number of subjects: 2000
Study 27986461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly titrated-dose oral misoprostol solution (20 μg hourly, increased to 40 μg and then to 60 μg)
Number of subjects: 146
Study 27986461 — intervention group
Group type: COMPARATOR
Intervention: 2-hourly static-dose oral misoprostol solution (25 μg every 2 hours)
Number of subjects: 146
Study 27986461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly titrated-dose oral misoprostol solution
Number of subjects: 146
Study 27986461 — intervention group
Group type: COMPARATOR
Intervention: 2-hourly static-dose oral misoprostol solution
Number of subjects: 146
Study 26356393 — intervention group
Group type: EXPERIMENTAL
Intervention: Divasa
Number of subjects: 40
Study 26356393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 40
Study 23315029 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 10 mg
Number of subjects: 60
Study 23315029 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 30 mg
Number of subjects: 60
Study 23315029 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg
Number of subjects: 60
Study 23315029 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg
Number of subjects: 60
Study 23315029 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg
Number of subjects: 60
Study 23315029 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (all doses)
Number of subjects: 60
Study 21075757 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin adhesive (Group 1)
Number of subjects: 368
Study 21075757 — intervention group
Group type: COMPARATOR
Intervention: Absorbable intracutaneous suture (Group 2)
Number of subjects: 368
Study 19261769 — intervention group
Group type: EXPERIMENTAL
Intervention: Zostavax
Number of subjects: 0
Study 17721555 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml bolus doses of 0.1% bupivacaine with butorphanol 2 mg (Group A)
Number of subjects: 20
Study 17721555 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of 0.25% plain bupivacaine (Group B)
Number of subjects: 20
Study 15534060 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-glass microspheres
Number of subjects: 27
Study 11822630 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9706733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (Topamax)
Number of subjects: 534
Study 7933501 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Number of subjects: 30
Study 7933501 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia (NLA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Number of subjects: 30
Study 7933501 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane Anesthesia (SA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Number of subjects: 30
Study 7933501 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 30
Study 7933501 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia (NLA)
Number of subjects: 30
Study 7933501 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane Anesthesia (SA)
Number of subjects: 30
Study 2904778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms, 2 puffs)
Number of subjects: 40
Study 2904778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 40
Study 30198624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse managers
Number of subjects: 339
Study 30198624 — intervention group
Group type: COMPARATOR
Intervention: Registered nurses
Number of subjects: 339
Study 28120486 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 (25-, 50-, 100-, and 200-mg single dose)
Number of subjects: 20
Study 28120486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26573448 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 90
Study 26573448 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoku point ice massage
Number of subjects: 90
Study 26573448 — intervention group
Group type: COMPARATOR
Intervention: Usual labor care
Number of subjects: 90
Study 23734921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and interpersonal group therapy
Number of subjects: 80
Study 21123833 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 244
Study 21123833 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 244
Study 18796160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d (300 mg BID)
Number of subjects: 167
Study 18796160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 17022857 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, titrated to 0.012 mg/kg/day
Number of subjects: 61
Study 17022857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 14620122 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanon (test)
Number of subjects: 15
Study 14620122 — intervention group
Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate (control)
Number of subjects: 15
Study 14620122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 15
Study 11087880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methylprednisolone and lidocaine (3 ml of 3 percent lidocaine with 60 mg of methylprednisolone acetate, 89 patients)
Number of subjects: 277
Study 11087880 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone (3 ml of 3 percent lidocaine, 91 patients)
Number of subjects: 277
Study 11087880 — intervention group
Group type: COMPARATOR
Intervention: No treatment (90 patients)
Number of subjects: 277
Study 9064551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy (DBT)
Number of subjects: 0
Study 9064551 — intervention group
Group type: COMPARATOR
Intervention: Unspecific psychotherapy
Number of subjects: 0
Study 1582300 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol DP capsules
Number of subjects: 30
Study 1582300 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol DP capsules
Number of subjects: 30
Study 1582300 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 micrograms formoterol DP capsules
Number of subjects: 30
Study 1582300 — intervention group
Group type: COMPARATOR
Intervention: 12 micrograms formoterol MDI
Number of subjects: 30
Study 1582300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 4075796 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vitamin supplementation (10 mg vitamin B6 daily or twice the dose daily for 7 non-hormone days)
Number of subjects: 0
Study 4075796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplements
Number of subjects: 0
Study 4075796 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous supplementation regimen
Number of subjects: 0
Study 4075796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent supplementation regimen
Number of subjects: 0
Study 4075796 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral contraceptive treatment
Number of subjects: 0
Study 31760846 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cedar solution plus clindamycin 1%
Number of subjects: 80
Study 31760846 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo plus 1% clindamycin
Number of subjects: 80
Study 31525542 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem-resistant ESBL-producing Enterobacterales (n=48, 27.4% of total isolates)
Number of subjects: 175
Study 31525542 — intervention group
Group type: EXPERIMENTAL
Intervention: blaNDM
Number of subjects: 175
Study 31525542 — intervention group
Group type: EXPERIMENTAL
Intervention: blaNDM/OXA-181
Number of subjects: 175
Study 31525542 — intervention group
Group type: EXPERIMENTAL
Intervention: blaOXA-181
Number of subjects: 175
Study 31525542 — intervention group
Group type: EXPERIMENTAL
Intervention: blaNDM/OXA-48
Number of subjects: 175
Study 31525542 — intervention group
Group type: EXPERIMENTAL
Intervention: No carbapenase detected
Number of subjects: 175
Study 31525542 — intervention group
Group type: EXPERIMENTAL
Intervention: MLST sequence types
Number of subjects: 175
Study 29381544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of small‐particle hyaluronic acid with lidocaine (SP‐HAL) microaliquots
Number of subjects: 20
Study 29381544 — intervention group
Group type: COMPARATOR
Intervention: Sham injection of sterile normal saline
Number of subjects: 20
Study 29381544 — intervention group
Group type: EXPERIMENTAL
Intervention: SP‐HAL treatment
Number of subjects: 20
Study 29381544 — intervention group
Group type: COMPARATOR
Intervention: Control cheek (normal saline)
Number of subjects: 20
Study 26840134 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 7 days
Number of subjects: 2399
Study 26840134 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 2399
Study 24214315 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 2
Study 22117732 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally rough implants (turned)
Number of subjects: 18
Study 22117732 — intervention group
Group type: COMPARATOR
Intervention: Moderately rough implants (TiUnite)
Number of subjects: 18
Study 22117732 — intervention group
Group type: COMPARATOR
Intervention: Comparison of clinical parameters between turned and TiUnite implants
Number of subjects: 18
Study 22117732 — intervention group
Group type: COMPARATOR
Intervention: Bone loss in partial edentulous subgroup
Number of subjects: 18
Study 19174782 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (150 mg daily)
Number of subjects: 17289
Study 19174782 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib (60 or 90 mg daily)
Number of subjects: 17289
Study 17701770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT), mean duration of exposure 8.3 years, 31% exposed for >=10 years
Number of subjects: 6755
Study 17701770 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed to HRT)
Number of subjects: 6755
Study 17701770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - route of administration
Number of subjects: 6755
Study 17701770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - type of HRT
Number of subjects: 6755
Study 16103769 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 460
Study 16103769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 460
Study 16103769 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 460
Study 16103769 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall resistance mutations
Number of subjects: 460
Study 11936169 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured training for 12 weeks via laptop computer
Number of subjects: 24
Study 11936169 — intervention group
Group type: COMPARATOR
Intervention: Incidental exposure to music in daily routine
Number of subjects: 24
Study 10530838 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Number of subjects: 84
Study 10530838 — intervention group
Group type: COMPARATOR
Intervention: Unicompartmental Knee Replacement (UKR)
Number of subjects: 84
Study 10530838 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR) with lateral release
Number of subjects: 84
Study 10530838 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR) without lateral release
Number of subjects: 84
Study 8577010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite 200 micrograms 5 to 7 times per week for 4 months
Number of subjects: 10
Study 8577010 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 10
Study 1955054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser iridotomy
Number of subjects: 52
Study 1955054 — intervention group
Group type: COMPARATOR
Intervention: Operative peripheral iridectomy
Number of subjects: 52
Study 6894722 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodoxamate
Number of subjects: 100
Study 6894722 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotroxamate
Number of subjects: 100
Study 30646403 — intervention group
Group type: EXPERIMENTAL
Intervention: High definition white-light colonoscopy
Number of subjects: 1855
Study 30646403 — intervention group
Group type: COMPARATOR
Intervention: Conventional white-light colonoscopy
Number of subjects: 1855
Study 30646403 — intervention group
Group type: COMPARATOR
Intervention: Virtual chromoendoscopy
Number of subjects: 1855
Study 30646403 — intervention group
Group type: COMPARATOR
Intervention: High definition virtual chromoendoscopy
Number of subjects: 1855
Study 28216083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 400IU or 4400IU per day during pregnancy
Number of subjects: 43
Study 27422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided recommendation on antibiotics (BAL fluid tested for IL-1β and IL-8 in addition to routine microbiology testing)
Number of subjects: 210
Study 27422026 — intervention group
Group type: COMPARATOR
Intervention: Routine use of antibiotics (BAL undergoes routine microbiology testing only)
Number of subjects: 210
Study 27422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided recommendation on antibiotics
Number of subjects: 210
Study 25117806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled blister packaging labeled for daily use with reminders (MeadWestvaco Corporation's pre-filled DosePak® containing standard doses of statins)
Number of subjects: 250
Study 25117806 — intervention group
Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 250
Study 25117806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled blister packaging
Number of subjects: 250
Study 21593282 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-sNT administered with 240 mL of 4% alcohol
Number of subjects: 32
Study 21593282 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-sNT administered with 240 mL of 20% alcohol
Number of subjects: 32
Study 21593282 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-sNT administered with 240 mL of 40% alcohol
Number of subjects: 32
Study 21593282 — intervention group
Group type: COMPARATOR
Intervention: MS-sNT administered with water
Number of subjects: 32
Study 19085741 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube-D (LT-D)
Number of subjects: 200
Study 19085741 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask (LMA)
Number of subjects: 200
Study 17561466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 57
Study 17561466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 15675212 — intervention group
Group type: EXPERIMENTAL
Intervention: +IV group (n=11)
Number of subjects: 22
Study 15675212 — intervention group
Group type: COMPARATOR
Intervention: -IV group (n=11)
Number of subjects: 22
Study 12613392 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga asanas (Suryanamskar, Tadasan, Konasan, Padmasan, Pranayam, Paschimottansan, Ardhmatsyendrasan, Shavasan, Pavanmukthasan, Sarpasan) performed for 30‐40 minutes every day for 40 days.
Number of subjects: 20
Study 12613392 — intervention group
Group type: COMPARATOR
Intervention: Control group (prescribed medication and light physical exercises like walking).
Number of subjects: 20
Study 10350956 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing social history information to house staff
Number of subjects: 134
Study 10350956 — intervention group
Group type: COMPARATOR
Intervention: Not providing social history information to house staff
Number of subjects: 134
Study 7651647 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (3.75 or 7.5 mg) in three monthly doses
Number of subjects: 46
Study 7651647 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (GnRH agonist)
Number of subjects: 46
Study 7651647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2613931 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive antibiotic TA (0.1 mg, 4 applications)
Number of subjects: 8
Study 2613931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 361346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (90 mg)
Number of subjects: 0
Study 361346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30255229 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of S-25(OH)D levels (105.3 nmol/L)
Number of subjects: 387
Study 30255229 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle quartiles of S-25(OH)D levels (74.5 nmol/L and 85.7 nmol/L)
Number of subjects: 387
Study 30255229 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of S-25(OH)D levels (59.3 nmol/L)
Number of subjects: 387
Study 30255229 — intervention group
Group type: EXPERIMENTAL
Intervention: All quartiles
Number of subjects: 387
Study 28647010 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Group Training (SSGT)
Number of subjects: 296
Study 28647010 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 296
Study 25052160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 48
Study 25052160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23875181 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention (EI) group
Number of subjects: 63
Study 23875181 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 63
Study 23875181 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 63
Study 21391759 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU of rFSH and 75 IU of rLH (group B)
Number of subjects: 999
Study 21391759 — intervention group
Group type: COMPARATOR
Intervention: 150 IU of rFSH (group A)
Number of subjects: 999
Study 19646194 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 24
Study 19646194 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg rosiglitazone
Number of subjects: 24
Study 19646194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17674415 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg three times per day, n = 17)
Number of subjects: 36
Study 17674415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 36